RNA
Price
$71.83
Change
+$0.23 (+0.32%)
Updated
Dec 12 closing price
Capitalization
10.82B
80 days until earnings call
Intraday BUY SELL Signals
ZBIO
Price
$40.59
Change
+$0.38 (+0.95%)
Updated
Dec 12 closing price
Capitalization
2.18B
74 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RNA vs ZBIO

Header iconRNA vs ZBIO Comparison
Open Charts RNA vs ZBIOBanner chart's image
Avidity Biosciences
Price$71.83
Change+$0.23 (+0.32%)
Volume$1.98M
Capitalization10.82B
Zenas Biopharma
Price$40.59
Change+$0.38 (+0.95%)
Volume$268.91K
Capitalization2.18B
RNA vs ZBIO Comparison Chart in %
RNA
Daily Signal:
Gain/Loss:
ZBIO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
RNA vs. ZBIO commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RNA is a Hold and ZBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (RNA: $71.60 vs. ZBIO: $40.21)
Brand notoriety: RNA and ZBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RNA: 32% vs. ZBIO: 45%
Market capitalization -- RNA: $10.82B vs. ZBIO: $2.18B
RNA [@Biotechnology] is valued at $10.82B. ZBIO’s [@Biotechnology] market capitalization is $2.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RNA’s FA Score shows that 0 FA rating(s) are green whileZBIO’s FA Score has 1 green FA rating(s).

  • RNA’s FA Score: 0 green, 5 red.
  • ZBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, both RNA and ZBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RNA’s TA Score shows that 3 TA indicator(s) are bullish while ZBIO’s TA Score has 2 bullish TA indicator(s).

  • RNA’s TA Score: 3 bullish, 5 bearish.
  • ZBIO’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, RNA is a better buy in the short-term than ZBIO.

Price Growth

RNA (@Biotechnology) experienced а +0.08% price change this week, while ZBIO (@Biotechnology) price change was +5.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

RNA is expected to report earnings on Mar 03, 2026.

ZBIO is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($10.8B) has a higher market cap than ZBIO($2.18B). ZBIO YTD gains are higher at: 390.965 vs. RNA (146.217). ZBIO has higher annual earnings (EBITDA): -195.62M vs. RNA (-609.06M). RNA has more cash in the bank: 1.88B vs. ZBIO (291M). ZBIO has less debt than RNA: ZBIO (798K) vs RNA (50M). RNA has higher revenues than ZBIO: RNA (20.9M) vs ZBIO (15M).
RNAZBIORNA / ZBIO
Capitalization10.8B2.18B496%
EBITDA-609.06M-195.62M311%
Gain YTD146.217390.96537%
P/E RatioN/A2.97-
Revenue20.9M15M139%
Total Cash1.88B291M645%
Total Debt50M798K6,266%
FUNDAMENTALS RATINGS
ZBIO: Fundamental Ratings
ZBIO
OUTLOOK RATING
1..100
26
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
30
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RNAZBIO
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
75%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
90%
Declines
ODDS (%)
Bearish Trend 23 days ago
87%
Bearish Trend 5 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RNA
Daily Signal:
Gain/Loss:
ZBIO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IONL47.491.29
+2.80%
GraniteShares 2x Long IONQ Daily ETF
MSFU42.010.88
+2.14%
Direxion Daily MSFT Bull 2X Shares
SOXS2.870.05
+1.77%
Direxion Daily Semicondct Bear 3X ETF
PSR91.000.15
+0.16%
Invesco Active US Real Estate
QQA53.87-0.18
-0.33%
Invesco QQQ Income Advantage ETF

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
+0.35%
DYN - RNA
60%
Loosely correlated
-1.37%
IDYA - RNA
50%
Loosely correlated
-0.24%
DSGN - RNA
48%
Loosely correlated
-1.91%
CRNX - RNA
48%
Loosely correlated
+2.60%
ZBIO - RNA
45%
Loosely correlated
+2.84%
More

ZBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZBIO has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBIO jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZBIO
1D Price
Change %
ZBIO100%
+2.84%
IDYA - ZBIO
50%
Loosely correlated
-0.24%
APGE - ZBIO
48%
Loosely correlated
+0.62%
SYRE - ZBIO
48%
Loosely correlated
-0.87%
RGNX - ZBIO
47%
Loosely correlated
-1.61%
IMNM - ZBIO
46%
Loosely correlated
-3.99%
More